We serve Chemical Name:5-Bromo-1,3-Difluoro-2-(Phenylmethoxy)-Benzene CAS:99045-18-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-Bromo-1,3-Difluoro-2-(Phenylmethoxy)-Benzene
CAS.NO:99045-18-8
Synonyms:1-Bromo-3,5-difluoro-4-(benzyloxy)benzene;4-BROMO-2,6-DIFLUORO-1-(BENZYLOXY)BENZENE
Molecular Formula:C13H9BrF2O
Molecular Weight:299.11100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:9.23000
Exact Mass:297.98000
LogP:4.30630
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-Bromo-3,5-difluoro-4-(benzyloxy)benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-BROMO-2,6-DIFLUORO-1-(BENZYLOXY)BENZENE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Bromo-3,5-difluoro-4-(benzyloxy)benzene Use and application,1-Bromo-3,5-difluoro-4-(benzyloxy)benzene technical grade,usp/ep/jp grade.
Related News: The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. (2R,3R,4R)-4-(tert-Butyl-diphenyl-silanyloxymethyl)-3-(4-methoxy-benzylsulfanyl)-oxetane-2-carboxylic acid dimethylamide manufacturers The additional GMP labs will be able to develop and manufacture highly potent API (HPAPI) under GMP standards. The expanded labs and manufacturing facilities are expected to come online between 1Q22 and 3Q22. 4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-benzyl-1,4-diazepan-2-one suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. ethyl 4-carbamothioylpiperazine-1-carboxylate vendor & factory.
